Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.62 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.61 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.61 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657997 | 0.87 | FFAR1 (0.67) | FFAR1LTB4RLTB4R2S1PR1S1PR3 | |
| SCHEMBL9123676 | 0.84 | LTB4R (0.58) | FFAR1LTB4RLTB4R2KMT2ALTA4H | |
| SCHEMBL4656572 | 0.79 | FFAR1 (0.97) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL1746597 | 0.78 | FFAR1 (1.00) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL8500544 | 0.77 | FFAR1 (0.67) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL4659369 | 0.77 | LTA4H (0.73) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL4658080 | 0.77 | FFAR1 (0.72) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL9120626 | 0.77 | LTB4R (0.53) | FFAR1LTB4RLTB4R2S1PR1S1PR3 | |
| SCHEMBL4657988 | 0.77 | FFAR1 (0.76) | FFAR1S1PR1S1PR3S1PR5PLA2G4B | |
| SCHEMBL4657720 | 0.77 | FFAR1 (0.76) | FFAR1S1PR1S1PR3S1PR5PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | claimed |
| US-8653305-B2 | Compound having S1P receptor binding potency and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8039674-B2 | Amino-substituted cyclic compound for EDG-1(endothelial differentiation gene) and/or EDG-6-mediated diseases; transplant rejection, autoimmune diseases, allergies, asthma, multiple organ failure, ischemia, reperfusion injury, lung or liver fibrosis; antitumor agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064060-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | S1PR1, S1PR3, EDNRA | FFAR1 50/4885LTB4R 37/4885LTB4R2 59/4885 |
| US-20080207584-A1 | Compound Having S1P Receptor Binding Potency and Use Thereof | S1PR1, EDNRA, S1PR3 | FFAR1 57/4885LTB4R 35/4885LTB4R2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.